Developer docs
API playgroundTry for free, no card

Search company profiles

Airfinity

Full company profile

uuid00078ly

Namestring
Airfinity
Legal namestring
Airfinity Limited
Websiteurl
airfinity.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Airfinity is an independent predictive analytics company, founded in 2015 and headquartered in London, that builds AI-powered health intelligence and forecasting solutions for the pharmaceutical industry, governments, and international health organizations. Its platform combines proprietary epidemiology models, machine learning, and disease-specialist analyst teams to deliver real-time forecasts and commercial intelligence across infectious disease, cardiometabolic/obesity, and adjacent therapy areas. The core product portfolio comprises six products: FRIDA (respiratory infectious disease forecasting), Airfinity Biorisk (biorisk surveillance across 160+ pathogens), Airfinity One ID (infectious disease intelligence used by 9 of the 10 largest pharma providers in infectious disease), Obesity Market Intelligence, CVRM Intelligence and Forecasting, and Nexa (drug and vaccine demand forecasting and simulation). These are supplemented by bespoke services including Second Opinion Forecasts, Competitive Intelligence, and Burden of Disease Modelling.

The company operates an enterprise go-to-market model, selling annual subscriptions via direct field sales with quote-based pricing and dedicated therapy-area analyst support. Its customer base spans pharma and biotech (AstraZeneca, GeoVax), national governments (UK Vaccine Task Force, White House Office of Pandemic Preparedness and Response Policy), international organizations (WHO), and academic institutions (University of Oxford). Revenue is generated through subscription-based analytics solutions layered with custom professional services. Airfinity maintains a globally distributed remote-first workforce of 101–250 employees and has expanded into APAC via a Japan regional office launched in March 2024. A single funding round (amount undisclosed) was disclosed in July 2022.

Short descriptiontext

Airfinity is a London-based, AI-powered predictive analytics company that delivers health intelligence and forecasting across infectious disease, obesity, and cardiometabolic conditions to pharmaceutical companies, governments, and international health organizations via enterprise subscriptions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
disease forecasting analytics, biopharma market intelligence, infectious disease surveillance, respiratory disease modeling, drug demand forecasting
Product category
Health Analytics & Forecasting Software
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Subscription-based Analytics Solutions
TypeSubscription Recurring
Description

Enterprise subscription model for access to predictive analytics platforms including FRIDA, Airfinity One ID, Airfinity Biorisk, Nexa, and CVRM/Obesity intelligence solutions

airfinity.com
2Custom Analytics and Consulting
TypeProfessional Services
Description

Bespoke analyst support and consulting services providing tailor-made solutions for specific business needs beyond standard offerings

airfinity.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Enterprise subscription pricing - details not publicly disclosed
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based / Not publicly disclosed. Multiple products offered including FRIDA, Biorisk, One ID, Nexa, Obesity Intelligence, CVRM Intelligence.

airfinity.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1FRIDA
Description

AI-powered forecasts for respiratory infectious disease dynamics, covering influenza, COVID-19, RSV, hMPV, ILI, ARI, and SARI across key global markets.

airfinity.com
+3 more records
Core offering1 text field

Airfinity operates an AI-powered predictive analytics platform that delivers real-time health intelligence, disease forecasting, and commercial analytics for the life sciences sector. Its core products cover infectious disease surveillance, respiratory disease forecasting, drug and vaccine demand simulation, and cardiometabolic/obesity market intelligence, all built on a proprietary epidemiology engine drawing from over one billion data points across 160+ diseases. Customers are primarily pharmaceutical companies, governments, and global health organizations that subscribe to enterprise analytics solutions or commission bespoke analyst support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 9 out of 10 largest pharmaceutical providers within infectious diseases rely on Airfinity One ID
+2 more records
Product overview1 text field

Airfinity is an independent predictive analytics company offering a unified platform of AI-powered health intelligence solutions. The core portfolio includes six main products: FRIDA™ for respiratory disease forecasting, Airfinity Biorisk for biorisk surveillance, Airfinity One ID for infectious disease intelligence, Obesity Market Intelligence, CVRM Intelligence and Forecasting for cardiovascular/renal/metabolic diseases, and Nexa for drug and vaccine demand forecasting. These products are complemented by custom analytical services including Second Opinion Forecasts, Competitive Intelligence, and Burden of Disease Modelling. The platform is built on over one billion data points and serves pharma companies, governments, and non-life science organizations across 160+ diseases.

Product and service1 record
1FRIDA
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Definitive Healthcare sells healthcare commercial intelligence and analytics to pharma, medtech, and providers. It is comparable in target customer and product category, though more focused on provider/claims data than disease forecasting.

TypeEmerging player
Description

Health Catalyst provides data and analytics infrastructure for health systems and life sciences. While more provider-focused, its life sciences analytics and outcomes products intersect with Airfinity's CVRM and disease burden offerings.

TypeBroad incumbent
Description

GlobalData provides industry intelligence across pharma, healthcare, and consumer verticals, including disease forecasts and pipeline analysis. It overlaps with Airfinity's commercial forecasting and disease intelligence offerings.

TypeBroad incumbent
Description

IQVIA is the largest contract research and healthcare data analytics firm globally. It serves the same pharma and government customers with a much broader portfolio, competing with Airfinity on commercial forecasting and real-world evidence.

TypeDirect peer
Description

Citeline provides pipeline, clinical trial, and commercial intelligence to pharma and biotech, overlapping heavily with Airfinity's One ID, Obesity, and CVRM products. It is one of the closest functional competitors in pharma pipeline intelligence.

TypeEmerging player
Description

Metabiota specialized in infectious disease risk analytics and outbreak intelligence, comparable to Airfinity's Biorisk product. Its integration into Ginkgo Bioworks repositioned it, but it remains a thematic peer in pandemic risk analytics.

TypeDirect peer
Description

Trinity Life Sciences delivers commercial analytics, forecasting, and competitive intelligence to pharma. It directly competes with Airfinity's Second Opinion Forecasts and Competitive Intelligence offerings for the same enterprise pharma buyers.

TypeBroad incumbent
Description

Clarivate offers pharma and biotech intelligence (e.g., Cortellis, Drug Launch) to overlapping enterprise customers. It competes indirectly with Airfinity's pipeline and competitive intelligence products as part of a much wider IP and analytics portfolio.

TypeDirect peer
Description

Evaluate (now part of Norstella) is the long-standing market leader in pharma forecasting and consensus sales analytics. It directly competes with Airfinity's commercial forecasting and pipeline intelligence offerings across the same pharma customer base.

10ZS Associates
TypeEmerging player
Description

ZS Associates combines consulting with proprietary pharma analytics and AI-driven sales/forecasting tools. It targets the same pharma commercial leaders as Airfinity and increasingly overlaps in AI-based demand forecasting.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Airfinity

Health Analytics & Forecasting Softwareairfinity.com

Airfinity is a London-based, AI-powered predictive analytics company that delivers health intelligence and forecasting across infectious disease, obesity, and cardiometabolic conditions to pharmaceutical companies, governments, and international health organizations via enterprise subscriptions.

What Airfinity does

Airfinity is an independent predictive analytics company, founded in 2015 and headquartered in London, that builds AI-powered health intelligence and forecasting solutions for the pharmaceutical industry, governments, and international health organizations. Its platform combines proprietary epidemiology models, machine learning, and disease-specialist analyst teams to deliver real-time forecasts and commercial intelligence across infectious disease, cardiometabolic/obesity, and adjacent therapy areas. The core product portfolio comprises six products: FRIDA (respiratory infectious disease forecasting), Airfinity Biorisk (biorisk surveillance across 160+ pathogens), Airfinity One ID (infectious disease intelligence used by 9 of the 10 largest pharma providers in infectious disease), Obesity Market Intelligence, CVRM Intelligence and Forecasting, and Nexa (drug and vaccine demand forecasting and simulation). These are supplemented by bespoke services including Second Opinion Forecasts, Competitive Intelligence, and Burden of Disease Modelling.

The company operates an enterprise go-to-market model, selling annual subscriptions via direct field sales with quote-based pricing and dedicated therapy-area analyst support. Its customer base spans pharma and biotech (AstraZeneca, GeoVax), national governments (UK Vaccine Task Force, White House Office of Pandemic Preparedness and Response Policy), international organizations (WHO), and academic institutions (University of Oxford). Revenue is generated through subscription-based analytics solutions layered with custom professional services. Airfinity maintains a globally distributed remote-first workforce of 101–250 employees and has expanded into APAC via a Japan regional office launched in March 2024. A single funding round (amount undisclosed) was disclosed in July 2022.

Airfinity firmographics

Firmographics
Name
Airfinity
Legal name
Airfinity Limited
Website
https://airfinity.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
Airfinity is a London-based, AI-powered predictive analytics company that delivers health intelligence and forecasting across infectious disease, obesity, and cardiometabolic conditions to pharmaceutical companies, governments, and international health organizations via enterprise subscriptions.
Ownership category
akta.pro rank

Where Airfinity is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Airfinity business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Subscription-based Analytics Solutions: Enterprise subscription model for access to predictive analytics platforms including FRIDA, Airfinity One ID, Airfinity Biorisk, Nexa, and CVRM/Obesity intelligence solutions
  2. Custom Analytics and Consulting: Bespoke analyst support and consulting services providing tailor-made solutions for specific business needs beyond standard offerings

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise subscription pricing - details not publicly disclosed

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Airfinity product offering

Product offering

Core offering

Airfinity operates an AI-powered predictive analytics platform that delivers real-time health intelligence, disease forecasting, and commercial analytics for the life sciences sector. Its core products cover infectious disease surveillance, respiratory disease forecasting, drug and vaccine demand simulation, and cardiometabolic/obesity market intelligence, all built on a proprietary epidemiology engine drawing from over one billion data points across 160+ diseases. Customers are primarily pharmaceutical companies, governments, and global health organizations that subscribe to enterprise analytics solutions or commission bespoke analyst support.

Product overview

Airfinity is an independent predictive analytics company offering a unified platform of AI-powered health intelligence solutions. The core portfolio includes six main products: FRIDA™ for respiratory disease forecasting, Airfinity Biorisk for biorisk surveillance, Airfinity One ID for infectious disease intelligence, Obesity Market Intelligence, CVRM Intelligence and Forecasting for cardiovascular/renal/metabolic diseases, and Nexa for drug and vaccine demand forecasting. These products are complemented by custom analytical services including Second Opinion Forecasts, Competitive Intelligence, and Burden of Disease Modelling. The platform is built on over one billion data points and serves pharma companies, governments, and non-life science organizations across 160+ diseases.

Differentiator

Problem solved

Functional benefit

Brands

  • FRIDA: AI-powered forecasts for respiratory infectious disease dynamics, covering influenza, COVID-19, RSV, hMPV, ILI, ARI, and SARI across key global markets.
  • Nexa
  • Airfinity Biorisk
  • Airfinity One ID

Products and services

  • FRIDA

Quantifiable outcome

  • 9 out of 10 largest pharmaceutical providers within infectious diseases rely on Airfinity One ID
  • +2 more outcomes

Companies that use Airfinity

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Airfinity technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Airfinity partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Airfinity competitors and assessment

Company assessment

Direct peers

  • Definitive Healthcare: Definitive Healthcare sells healthcare commercial intelligence and analytics to pharma, medtech, and providers. It is comparable in target customer and product category, though more focused on provider/claims data than disease forecasting.
  • Citeline (Informa Pharma Intelligence): Citeline provides pipeline, clinical trial, and commercial intelligence to pharma and biotech, overlapping heavily with Airfinity's One ID, Obesity, and CVRM products. It is one of the closest functional competitors in pharma pipeline intelligence.
  • Trinity Life Sciences: Trinity Life Sciences delivers commercial analytics, forecasting, and competitive intelligence to pharma. It directly competes with Airfinity's Second Opinion Forecasts and Competitive Intelligence offerings for the same enterprise pharma buyers.
  • Evaluate (Norstella): Evaluate (now part of Norstella) is the long-standing market leader in pharma forecasting and consensus sales analytics. It directly competes with Airfinity's commercial forecasting and pipeline intelligence offerings across the same pharma customer base.

Emerging players

  • Health Catalyst: Health Catalyst provides data and analytics infrastructure for health systems and life sciences. While more provider-focused, its life sciences analytics and outcomes products intersect with Airfinity's CVRM and disease burden offerings.
  • Metabiota (now part of Ginkgo Bioworks): Metabiota specialized in infectious disease risk analytics and outbreak intelligence, comparable to Airfinity's Biorisk product. Its integration into Ginkgo Bioworks repositioned it, but it remains a thematic peer in pandemic risk analytics.
  • ZS Associates: ZS Associates combines consulting with proprietary pharma analytics and AI-driven sales/forecasting tools. It targets the same pharma commercial leaders as Airfinity and increasingly overlaps in AI-based demand forecasting.

Broad incumbents

  • GlobalData: GlobalData provides industry intelligence across pharma, healthcare, and consumer verticals, including disease forecasts and pipeline analysis. It overlaps with Airfinity's commercial forecasting and disease intelligence offerings.
  • IQVIA: IQVIA is the largest contract research and healthcare data analytics firm globally. It serves the same pharma and government customers with a much broader portfolio, competing with Airfinity on commercial forecasting and real-world evidence.
  • Clarivate: Clarivate offers pharma and biotech intelligence (e.g., Cortellis, Drug Launch) to overlapping enterprise customers. It competes indirectly with Airfinity's pipeline and competitive intelligence products as part of a much wider IP and analytics portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Airfinity social profiles

Digital presence

Airfinity financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Airfinity leadership team

Management profile

Number of profiles

Profiles10 records

Airfinity subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Airfinity funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Airfinity M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Airfinity

What does Airfinity do?

Airfinity operates an AI-powered predictive analytics platform that delivers real-time health intelligence, disease forecasting, and commercial analytics for the life sciences sector. Its core products cover infectious disease surveillance, respiratory disease forecasting, drug and vaccine demand simulation, and cardiometabolic/obesity market intelligence, all built on a proprietary epidemiology engine drawing from over one billion data points across 160+ diseases. Customers are primarily pharmaceutical companies, governments, and global health organizations that subscribe to enterprise analytics solutions or commission bespoke analyst support.

Is Airfinity a public or private company?

Airfinity is a private company. It is classified as venture growth investor backed and is currently operating.

When was Airfinity founded?

Airfinity was founded in 2015. It employs 51 to 100 people.

Where is Airfinity based?

Airfinity is headquartered in London, United Kingdom, in the Europe region.

How does Airfinity make money?

Two revenue lines are on record. Subscription-based Analytics Solutions are the primary driver. The others are custom Analytics and Consulting.

Who are Airfinity's main competitors?

Direct peers on record are Definitive Healthcare, Citeline (Informa Pharma Intelligence), Trinity Life Sciences and Evaluate (Norstella). Emerging players are Health Catalyst, Metabiota (now part of Ginkgo Bioworks) and ZS Associates. Broad incumbents are GlobalData, IQVIA and Clarivate.

Does Airfinity have an API?

No public API is recorded for Airfinity.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Straits TimesViral load: Hantavirus may linger in semen for 6 years and be transmitted via sex, study findsResearchers at Switzerland's Spiez Laboratory published a peer-reviewed study in 2023 finding that the Andes strain of hantavirus can persist in human semen for nearly six years after initial infection, even after the virus has disappeared from blood, urine, and respiratory tract. The study examined a 55-year-old Swiss man who contracted the virus while traveling in South America, with viral traces detected in his semen 71 months later. While no confirmed case of sexual transmission has been documented, analysts at Airfinity have recommended that male Andes virus survivors receive extended safe-sex guidance similar to protocols for Ebola survivors.AirfinityPredictive Health Intelligence & Data AnalyticsAirfinity positions itself as a provider of predictive health intelligence and data analytics that tracks, simulates, and predicts population-level disease outcomes. The company utilizes dynamic forecasting models to support activities such as clinical trial site optimization, scenario-based demand intelligence, and resource allocation decisions for medical countermeasures.Business InsiderChina is likely seeing over a million COVID cases and 5,000 deaths a day, report says. But Beijing's official data is showing 7 deaths so far this week.Airfinity's data modelling estimates China is seeing over 1 million daily COVID cases and 5,000 deaths, contrasting with official figures of 14,285 cases and seven deaths this week. The company predicts two peaks, with cases reaching 3.7 million daily in mid-January and 4.2 million in early March 2023.The Independent1.1 billion Covid vaccine doses wasted globally, estimates suggestAirfinity estimates 1.1 billion Covid vaccine doses were wasted globally, with public reports showing 158 million discarded. Russia's Sputnik V had the highest wastage at 25 million doses, followed by AstraZeneca at 19 million. The analysis assumes a 10% wastage rate from June 2021.Bloomberg Law NewsCovid Vaccine Sales Projected to Pick Up After Steep DropCovid vaccine sales from Pfizer and Moderna fell about 60% over the last three months as countries reduced purchases. Demand is expected to rise in the second half of the year, with variant-targeting vaccines potentially making up over a fifth of the market in 2022 if introduced this fall.CgtnChina's COVID-19 vaccine exports saved 3m lives, says UK studyA UK study by Airfinity estimated that Chinese vaccines Sinovac and Sinopharm saved over 3 million lives outside China in the first year of the global vaccination campaign. The study excluded China's figures to avoid skewing estimates, and AstraZeneca and Pfizer-BioNTech saved the most lives.ScientificamericanMonopolies Are Getting in the Way of mRNA VaccinesThe author argues that mRNA vaccine monopolies by Moderna, Pfizer, and BioNTech block access for poor countries, citing 93% of ordered doses going to rich nations. He notes that while these firms plan new factories, they take years to become operational, leaving vulnerable populations unprotected.The IndependentUK among worst offenders in G7 vaccine supply failures ‘which led to 600,000 preventable deaths’ in poorer countriesThe UK and Canada were named among the worst G7 offenders for failing to deliver promised vaccine doses to poorer countries, leading to 600,000 preventable deaths. Only 39% of the UK's 100 million dose pledge has been delivered, and less than half of G7 donations have been distributed.The TelegraphBritain has delivered just 39pc of Covid vaccines promised to poorer countriesBritain delivered only 39% of the 100 million Covid vaccines it pledged to poorer countries, with no G7 member meeting its targets. The UK, Canada, and others fell short, while Germany and Japan exceeded 60%. The analysis was commissioned by the People's Vaccine Alliance ahead of the G7 summit.